5-Star Stocks Poised to Pop: Novartis
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Swiss pharmaceutical giant Novartis (NYS: NVS) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Novartis' business and see what CAPS investors are saying about the stock right now.
Novartis facts
Headquarters (founded) | Basel, Switzerland (1895) |
Market Cap | $141.2 billion |
Industry | Pharmaceuticals |
Trailing-12-Month Revenue | $59.1 billion |
Management | CEO Joseph Jimenez |
Return on Equity (average, past 3 years) | 16.2% |
Cash/Debt | $5.4 billion / $24.6 billion |
Dividend Yield | 4.8% |
Competitors | Merck |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 1,563 members who have rated Novartis believe the stock will outperform the S&P 500 going forward.
Just yesterday, one of those Fools, troym72, tapped the stock as an attractive bargain opportunity:
Okay, its getting hard to ignore the fact that the forward P/E is under 10 and the [dividend yield] is now over 4%. I really don't think a person could go wrong with [Novartis] at this point. But, then I have been wrong before. [Novartis] has strategic partnerships (such as the one with [Zalicus]) that appear to be very promising as well.
If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, Novartis may not be your top choice.
If that's the case, we've compiled a special free report for investors called "Secure Your Future With 9 Rock-Solid Dividend Stocks," which uncovers several other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the newTrackPoisedToCAPS account.
At the time thisarticle was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
